Skip to main content

Table 2 Pulsed-field types, antimicrobial resistance, and resistance and virulence genes, of methicillin-resistant S. aureus (MRSA) and methicillin-susceptible S. aureus (MSSA) isolates from personnel screened in the US and Afghanistan

From: Staphylococcus aureus colonization of healthy military service members in the United States and Afghanistan

  MRSA MSSA
US Afghan Total  US  Afghan  Total
Pulsed-field types a 4 4 8  42 35 77
 Community-associated isolates n(%) 3(75) 1(25) 4(50)  4(10)  3(9)  7 (9)
  USA 300 3(75)c 1(25) 4(50)d  2(5)c  2(6)  4(5)d
  USA 400 0 0 0  2(5)  1(3)  3(4)
 Healthcare-associated isolates n(%) 1(25) 3(75) 4(50) 38(90) 32(91) 70(91)
  USA 200 0 0 0  9(21)  6(17) 15(20)
  USA 500 0 0 0  0  5(14)  5(6)
  USA 600 0 0 0  2(5)  1(3)  3(4)
  USA 700 1(25) 0 1(12)  0  2(6)  2(3)
  USA 800 0 1(25) 1(12)  7(16)  7(20) 14(18)
  USA 900 0 0 0  5(12)  2(6)  7(9)
  USA 1000 0 2(50) 2(12)  2(5)  5(14)  7(9)
 Other (%) 0 0 0 13(31)  4(11) 17(22)
Antimicrobial susceptibility and presence of antimicrobial resistance gene n(%) b 4 4 8 47 35 82
 Ampicillin 0 0 0  0  0  0
 Ampicillin-sulbactam 0 0 0e 47(100) 35(100) 82(100)e
 Penicillin G 0 0 0 10(21)  6(17) 16(19)
  blaZ 4(100) 4(100) 8(100) 36(77) 29(83) 65(79)
 Clindamycin 3(75) 4(100) 7 (87) 39(83) 29(83) 68(83)
  ermA 0 0 0  8(17)  4(11) 12(15)
  ermB and ermT 0 0 0  0  0  0
  ermC 1(25) 0(0) 1 (12)  0  0  0
 Erythromycin 0 1(25) 1 (12)f 34(72) 22(63) 56(68)f
  msrA 3(75)g 3(75) 6(75)h 2(4)g  8(23) 10(12)h
  ermA 1(25) 0 1(12) 8(17)  4(11) 12(15)
 Levofloxacin 2(50)i 4(100) 6(75)j 46(98)i 35(100) 81(99)j
 Moxifloxacin 2(50)k 4(100) 6(75)l 46(98)k 35(100) 81(99)l
 Rifampin 4(100) 4(100) 8(100) 47(100) 35(100) 82(100)
 Doxycycline 4(100) 4(100) 8(100) 46(98) 33(94) 79 (98)
 Minocycline 4(100) 4(100) 8(100) 47(100) 33(94) 80(98)
 Tetracycline 4(100) 4(100) 8(100) 46(98) 25(71) 71(87)
  tetK 0 0 0  0m  6(17)m  6(7)
  tetL and tetO 0 0 0  0  0  0
  tetM 0 0 0  1(2)n  2(6)n  3(4)
 Trimethoprim - sulfamethoxazole 4(100) 4(100) 8(100) 45(96) 35(100) 80(98)
  dfrA and dfrK 0 0 0  0  0  0
Other resistance and virulence markers (%) b 4 4 8 47 35 82
 mecA 4(100) 4(100) 8(100)  0  0  0
 SCCmec 4(100) 4(100) 8(100)  0  0  0
 PVL 1(25) 1(25) 2(25)o  1(2)  1(3)  2(2)o
 ACME 2(50)p 1(25) 3(37)q  0p  0  0q
 Agr I 4(100) 1(25) 5(62) 15(32) 11(31) 26(32)
 Agr II 0 1(25) 1(12) 15(32) 12(34) 27(33)
 Agr III 0 0 0  0r 11(31)r 11(13)
  1. a Includes isolates with unique PFTs that were also unique to an individual study participant.
  2. b Includes isolates that were unique to individual study participants.
  3. Statistically significant differences (p <0.05):
  4. cUSA 300 in MRSA vs. MSSA colonized personnel for the US personnel.
  5. dUSA 300 in MRSA vs. MSSA colonized personnel for the total personnel.
  6. eAmpicillin-sulbactam susceptibility in MRSA vs. MSSA colonized personnel for the total personnel.
  7. fErythromycin susceptibility in MRSA vs. MSSA colonized personnel for the total personnel.
  8. gmsrA gene presence in MRSA vs. MSSA colonized personnel for the US personnel.
  9. hmsrA gene presence in MRSA vs. MSSA colonized personnel for the total personnel.
  10. iLevofloxacin susceptibility in MRSA vs. MSSA colonized personnel for the US personnel.
  11. jLevofloxacin susceptibility in MRSA vs. MSSA colonized personnel for the total personnel.
  12. kMoxifloxacin susceptibility in MRSA vs. MSSA colonized personnel for the US personnel.
  13. lMoxifloxacin susceptibility in MRSA vs. MSSA colonized personnel for the total personnel.
  14. mtetK presence in MSSA colonized personnel for US vs. Afghan personnel.
  15. ntetM presence in MSSA colonized personnel for US vs. Afghan personnel.
  16. oPVL presence in MRSA vs. MSSA colonized personnel for the total personnel.
  17. pACME presence in MRSA vs. MSSA colonized personnel in US personnel.
  18. qACME presence in MRSA vs. MSSA colonized personnel in total personnel.
  19. rAgr III presence in MSSA colonized personnel for US vs. Afghanistan personnel.